Subjects’ baseline characteristics

Post-COVID (n = 45)Controls (n = 52)a
Age (mean) (range) (yr)58 (18–87)57 (24–73)
Male sex (No.) (%)24 (53.33)28 (53.85)
[18F] FDG administered dose (mean) (SD) (mCi)12.28 (3.18)11.88 (2.59)
BMI (mean) (SD) (kg/m2)28.62 (7.59)28.45 (6.36)
Glucose levels (mean) (SD) (mg/dL)95.13 (22.90)98.04 (23.82)
Diabetes (No.) (%)3 (6.67)6 (11.54)
High blood pressure (No.) (%)14 (31.11)21 (40.38)
Delay between positive RT-PCR and imaging (mean) (SD) (mo)6.57 (4.85)–
COVID-19 severity mild/moderate or severe (No.) (%)37/8 (82.22/17.78)–
Hospitalization (No.) (%)15 (33.33%)
Oxygen supplementation (No.) (%)9 (20.00%)
Mechanical ventilation (No.) (%)2 (4.44%)
COVID-19 vaccine at any time before [18F] FDG-PET scan (No.) (%)28 (62.2)–
Symptoms (No.) (%)
 Dysosmia/dysgeusiab17 (37.80)–
 Fever16 (35.6)–
 Chills6 (13.3)–
 Cough16 (35.6)–
 Dyspnea8 (17.8)–
 Chest pain2 (4.4)–
 Pharyngitis4 (8.9)–
 Rhinitis3 (6.7)–
 Headache4 (8.9)–
 Fatigue7 (15.6)–
 Muscular pain1 (2.2)–
 Dysgeusia1 (2.2)–
 Anosmia/hyposmia1 (2.2)–
 Diarrhea4 (8.9)–
 Loss of appetite2 (4.4)–
Neurologic symptoms at time of imaging (No.) (%)c
 Persistent headaches3 (6.7)
 Memory impairment1 (2.2)
 Difficulty concentrating1 (2.2)
 Fatigue1 (2.2)
 Insomnia1 (2.2)

  • Note:—The en dash indicates not applicable.

  • ↵a No statistically significant difference was observed between patients post-COVID and sex- and age-matched controls (P < .05, 2-sample t test for continuous variables, χ2 test for dichotomous variables).

  • ↵b Between the time of the initial diagnosis and PET imaging. All other symptoms pertain to the time of the initial diagnosis.

  • ↵c Persistent symptoms following COVID-19 infection that were reported in the patients’ records dating no more than 7 days before PET imaging.